New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance

International Journal of Antimicrobial Agents

Volumn 47, Issue 4, 2016, Pages 250-258

  Syue, Ling Shan ^a   Chen, Yen Hsu ^b,c   Ko, Wen Chien ^a,d   Hsueh, Po Ren ^e  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antimicrobial resistance; Avibactam; Ceftolozane; Eravacycline; Intra abdominal infections; Plazomicin

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM PLUS AZTREONAM; AVIBACTAM PLUS CEFTAZIDIME; BAL 30072; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEMASE; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN; DALBAVANCIN; DELAFLOXACIN; ERAVACYCLINE; EXTENDED SPECTRUM BETA LACTAMASE; FINAFLOXACIN; IMIPENEM PLUS RELEBACTAM; MEROPENEM PLUS RPX 2009; MONOBACTAM DERIVATIVE; NEW DRUG; ORITAVANCIN; PLAZOMICIN; RADEZOLID; RELEBACTAM; RPX 2009; S 649266; TEDIZOLID; TELAVANCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEASIBILITY STUDY; HUMAN; INFECTION COMPLICATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; BACTERIAL INFECTIONS; INTRAABDOMINAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS; INTRAABDOMINAL INFECTIONS;

EID: 84961226195     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.12.021     Document Type: Short Survey

References (94)

1. J.S. Solomkin, J.E. Mazuski, E.J. Baron, R.G. Sawyer, A.B. Nathens, J.T. DiPiro, and et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections Clin Infect Dis 37 2003 997 1005
2. N.V. Christou, P.S. Barie, E.P. Dellinger, J.P. Waymack, and H.H. Stone Surgical Infection Society intra-abdominal infection study: prospective evaluation of management techniques and outcome Arch Surg 128 1993 193 198
3. J.S. Solomkin, J.E. Mazuski, J.S. Bradley, K.A. Rodvold, E.J. Goldstein, E.J. Baron, and et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America Clin Infect Dis 50 2010 133 164
4. M. Sartelli, P. Viale, F. Catena, L. Ansaloni, E. Moore, M. Malangoni, and et al. WSES guidelines for management of intra-abdominal infections World J Emerg Surg 8 2013 3
5. Y.P. Chong, I.G. Bae, S.R. Lee, J.W. Chung, J.B. Jun, E.J. Choo, and et al. Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections PLOS ONE 10 2015 e0119956
6. M. Sartelli, F. Catena, L. Ansaloni, F. Coccolini, D. Corbella, E.E. Moore, and et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study World J Emerg Surg 9 2014 37
7. M. Sartelli, F. Catena, L. Ansaloni, A. Leppaniemi, K. Taviloglu, H. van Goor, and et al. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study World J Emerg Surg 7 2012 36
8. D.L. Paterson, F. Rossi, F. Baquero, P.R. Hsueh, G.L. Woods, V. Satishchandran, and et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART) J Antimicrob Chemother 55 2005 965 973
9. S.P. Hawser, S.K. Bouchillon, D.J. Hoban, and R.E. Badal In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study Int J Antimicrob Agents 34 2009 585 588
10. S.S. Jean, W.S. Lee, K.J. Bai, C. Lam, C.W. Hsu, K.W. Yu, and et al. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007 J Microbiol Immunol Infect 48 2015 85 91
11. C.C. Huang, Y.S. Chen, H.S. Toh, Y.L. Lee, Y.M. Liu, C.M. Ho, and et al. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010 Int J Antimicrob Agents 40 Suppl. 2012 S4 S10
12. P.R. Hsuech Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010 Int J Antimicrob Agents 40 Suppl. 2012 S1 S3
13. W.H. Sheng, R.E. Badal, and P.R. Hsueh Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART) Antimicrob Agents Chemother 57 2013 2981 2988
14. K.M. Kazmierczak, S.H. Lob, D.J. Hoban, M.A. Hackel, R.E. Badal, and S.K. Bouchillon Characterization of extended-spectrum β-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends Diagn Microbiol Infect Dis 82 2015 209 214
15. M. Castanheira, R.E. Mendes, L.N. Woosley, and R.N. Jones Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09) J Antimicrob Chemother 66 2011 1409 1411
16. C.K. Tan, H.J. Tang, C.C. Lai, Y.Y. Chen, P.C. Chang, and W.L. Liu Correlation between antibiotic consumption and carbapenem-resistant Acinetobacter baumannii causing health care-associated infections at a hospital from 2005 to 2010 J Microbiol Immunol Infect 48 2015 540 544
17. W.A. Hayajneh, A. Haji, F. Hulliel, D.K. Sarkis, N. Irani-Hakimeh, L. Kazan, and et al. Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011-2013 Int J Infect Dis 35 2015 56 61
18. Y.L. Lee, Y.S. Chen, H.S. Toh, C.C. Huang, Y.M. Liu, C.M. Ho, and et al. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010 Int J Antimicrob Agents 40 Suppl. 2012 S29 S36
19. S.P. Hawser, R.E. Badal, S.K. Bouchillon, D.J. Hoban, M.A. Hackel, D.J. Biedenbach, and et al. Susceptibility of Gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011 J Infect 68 2014 71 77
20. Y.M. Liu, Y.S. Chen, H.S. Toh, C.C. Huang, Y.L. Lee, C.M. Ho, and et al. In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Int J Antimicrob Agents 40 Suppl. 2012 S11 S17
21. R. Badal, S. Lob, S. Bouchillon, D. Hoban, S. Hawser, J. Johnson, and et al. Susceptibility of intra-abdominal pathogens in Europe, Africa and Middle East - SMART 2010/2011 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Annual Meeting 31 March-3 April 2012, London, UK 2012 ESCMID Basel, Switzerland
22. S.P. Hawser, R.E. Badal, S.K. Bouchillon, D.J. Hoban, D.J. Biedenbach, R. Cantón, and et al. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010 Int J Antimicrob Agents 41 2013 224 228
23. R. Badal, S. Bouchillon, M. Hackel, D. Hoban, A. Johnson, and S. Hawser Global susceptibility and ESBL+ rates of K. pneumoniae from intra-abdominal infections - SMART 2011 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 9-12 September 2012, San Francisco, CA 2012 ASM Press Washington, DC
24. B.R. Swenson, R. Metzger, T.L. Hedrick, S.T. McElearney, H.L. Evans, R.L. Smith, and et al. Choosing antibiotics for intra-abdominal infections: what do we mean by 'high risk'? Surg Infect (Larchmt) 10 2009 29 39
25. H.S. Sader, A. Hsiung, T.R. Fritsche, and R.N. Jones Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype Diagn Microbiol Infect Dis 57 2007 341 344
26. A. Toda, H. Ohki, T. Yamanaka, K. Murano, S. Okuda, K. Kawabata, and et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205 Bioorg Med Chem Lett 18 2008 4849 4852
27. G.G. Zhanel, P. Chung, H. Adam, S. Zelenitsky, A. Denisuik, F. Schweizer, and et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli Drugs 74 2014 31 51
28. D.R. Snydman, L.A. McDermott, and N.V. Jacobus Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates Antimicrob Agents Chemother 58 2014 1218 1223
29. D.M. Livermore, S. Mushtaq, and Y. Ge Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase-producing Enterobacteriaceae J Antimicrob Chemother 65 2010 1972 1974
30. C. Lucasti, E. Hershberqer, B. Miller, S. Yankelev, J. Steenbergen, I. Friedland, and et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections Antimicrob Agents Chemother 58 2014 5350 5357
31. J. Solomkin, E. Hershberqer, B. Miller, M. Popejoy, I. Friedland, J. Steenbergen, and et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI) Clin Infect Dis 60 2015 1462 1471
32. K. Coleman Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors Curr Opin Microbiol 14 2011 550 555
33. G.G. Zhanel, C.D. Lawson, H. Adam, F. Schweizer, S. Zelenitsky, P.R. Lagace-Wiens, and et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination Drugs 73 2013 159 177
34. P. Levasseur, A.M. Girard, C. Miossec, J. Pace, and K. Coleman In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases Antimicrob Agents Chemother 59 2015 1931 1934
35. P. Levasseur, A.M. Girard, M. Claudon, H. Goossens, M.T. Black, K. Coleman, and et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates Antimicrob Agents Chemother 56 2012 1606 1608
36. D.M. Citron, K.L. Tyrrell, V. Merriam, and E.J. Goldstein In vitro activity of ceftazidime-NXL104 against 396 strains of β-lactamase-producing anaerobes Antimicrob Agents Chemother 55 2011 3616 3620
37. H.S. Sader, M. Castanheria, R.K. Flamm, D.J. Farrell, and R.N. Jones Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012 Antimicrob Agents Chemother 58 2014 1684 1692
38. R.K. Shields, C.J. Clancy, B. Hao, L. Chen, E.G. Press, N.M. Iovine, and et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant Klebsiella pneumoniae Antimicrob Agents Chemother 59 2015 5793 5797
39. C. Lucasti, I. Popescu, M.K. Ramesh, J. Lipka, and C. Sable Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial J Antimicrob Chemother 68 2013 1183 1192
40. Forest Pharmaceuticals Inc. Avycaz highlights of prescribing information. Cincinnati, OH: Forest Pharmaceuticals Inc. http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/206494s000lbl.pdf [accessed 19.01.16].
41. M.U. Rashid, S. Rosenborq, G. Panagiotidis, K.S. Löfdal, A1 Weintraub, and C.E. Nord Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota Int J Antimicrob Agents 46 2015 60 65
42. R. Singh, A. Kim, M.A. Tanudra, J.J. Harris, R.E. McLaughlin, S. Patey, and et al. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam J Antimicrob Chemother 70 2015 2618 2626
43. D.J. Biedenbach, K. Kazmierczak, S.K. Bouchillon, D.F. Sahm, and P.A. Bradford In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013 Antimicrob Agents Chemother 59 2015 4239 4248
44. S.S. Jean, W.S. Lee, and P.R. Hsueh Nationwide spread of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan J Microbiol Immunol Infect 46 2013 317 319
45. ClnicalTrials.gov. To investigate the safety and tolerability of aztreonam-avibactam (ATM-AVI). Identifier NCT01689207. https://clinicaltrials.gov/ct2/show/NCT01689207?term=aztreonam+avibactam&rank=1 [accessed 19.01.16].
46. K.A. Toussaint, and J.C. Gallagher β-Lactam/β-lactamase inhibitor combinations: from then to now Ann Pharmacother 49 2015 86 98
47. A. Lapuebla, M. Abdallah, O. Olafisoye, C. Cortes, C. Urban, D. Landman, and et al. Activity of imipenem with relebactam against Gram-negative pathogens from New York City Antimicrob Agents Chemother 59 2015 5029 5031
48. E.B. Hirsch, K.P. Ledesma, K.T. Chang, M.S. Schwartz, M.R. Motyl, and V.H. Tam In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria Antimicrob Agents Chemother 56 2012 3753 3757
49. ClinicalTrials.gov. Study of the safety, tolerability, and efficacy of MK-7655+ imipenem/cilastatin versus imipenem/cilastatin alone to treat complicated intra-abdominal infection [cIAI] (MK-7655-004). Identifier NCT01506271. https://clinicaltrials.gov/ct2/show/NCT01506271?term=MK-7655&rank=1 [accessed 19.01.16].
50. S.J. Hecker, K.R. Reddy, M. Totrov, G.C. Hirst, O. Lomovskaya, D.C. Griffith, and et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases J Med Chem 58 2015 3682 3692
51. A. Lapuebla, M. Abdallah, O. Olafisoye, C. Cortes, C. Urban, J. Quale, and et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City Antimicrob Agents Chemother 59 2015 4856 4860
52. ClinicalTrials.gov. Efficacy, safety, tolerability of Carbavance compared to best available therapy in serious infections due to carbapenem resistant Enterobacteriaceae, in adults. Identifier: NCT02168946. https://clinicaltrials.gov/ct2/show/NCT02168946 [accessed 19.01.16].
53. A. Ito, S. Toba, T. Nishikawa, M. Oota, S. Kanazawa, N. Fukuhara, and et al. S-649266, a novel siderophore cephalosporin: binding affinity to PBP and bactericidal activity 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 25-28 April 2015, Copenhagen, Denmark 2015 ESCMID Basel, Switzerland
54. U. Möllmann, L. Heinisch, A. Bauernfeind, T. Köhler, and D. Ankel-Fuchs Siderophores as drug delivery agents: application of the 'Trojan Horse' strategy Biometals 22 2009 615 624
55. N. Kohira, J. West, A. Ito, T. Ito-Horiyama, R. Nakamura, T. Sato, and et al. In vitro antimicrobial activity of siderophore cephalosporin S-649266 against Enterobacteriaceae clinical isolates including carbapenem-resistant strains Antimicrob Agents Chemother 2015, November [Epub ahead of print]
56. M. Tsuji, A. Ito, R. Nakamura, Y. Yamano, and J. Shimada S-649266, a novel siderophore cephalosporin: in vitro activity against Gram-negative bacteria Open Forum Infect Dis 1 Suppl. 1 2014 S108
57. ClinicalTrials.gov. Efficacy and safety of intravenous S-649266 versus intravenous imipenem/cilastatin in complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis caused by Gram-negative pathogens in hospitalized adults. Identifier: NCT02321800. https://clinicaltrials.gov/ct2/show/NCT02321800?term=S649266&rank=1 [accessed 19.01.16].
58. D. Landman, M. Singh, B. El-Imad, E. Miller, T. Win, and J. Quale In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates Int J Antimicrob Agents 43 2014 527 532
59. M. Hornsey, L. Phee, W. Stubbings, and D.W. Wareham In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens Int J Antimicrob Agents 42 2013 343 346
60. X.Y. Xiao, D.K. Hunt, J. Zhou, R.B. Clark, N. Dunwoody, C. Fyfe, and et al. Fluorocyclines 1,7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent J Med Chem 55 2012 597 605
61. R.B. Clark, D.K. Hunt, M. He, C. Achorn, C.L. Chen, Y. Deng, and et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy J Med Chem 55 2012 606 622
62. J.A. Sutcliffe, W. O'Brien, C. Fyfe, and T.H. Grossman Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens Antimicrob Agents Chemother 57 2013 5548 5558
63. J.S. Solomkin, M.K. Ramesh, G. Cesnauskas, N. Novikovs, P. Stefanova, J.A. Sutcliffe, and et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections Antimicrob Agents Chemother 58 2014 1847 1854
64. ClinicalTrials.gov. Efficacy and safety study of eravacycline compared with ertapenem in complicated intra-abdominal infections. Identifier: NCT01844856. https://clinicaltrials.gov/ct2/show/NCT01844856?term=eravacycline&rank=1 [accessed 19.01.16].
65. M. Bassetti, and E. Righi Eravacycline for the treatment of intra-abdominal infections Expert Opin Investig Drugs 23 2014 1575 1584
66. G.G. Zhanel, C.D. Lawson, S. Zelenitsky, B. Findlay, F. Schweizer, H. Adam, and et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin Expert Rev Anti Infect Ther 10 2012 459 473
67. I. Galani, M. Souli, G.L. Daikos, Z. Chrysouli, G. Poulakou, M. Psichogiou, and et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece J Chemother 24 2012 191 194
68. D.M. Livermore, S. Mushtaq, M. Warner, J.C. Zhang, S. Maharjan, M. Doumith, and et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates J Antimicrob Chemother 66 2011 48 53
69. R.T. Cass, C.D. Brooks, N.A. Havrilla, K.J. Tack, M.T. Borin, D. Young, and et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects Antimicrob Agents Chemother 55 2011 5874 5880
70. ClinicalTrials.gov. A study of plazomicin compared with colistin in patients with infection due to carbapenem-resistant Enterobacteriaceae (CRE) (CARE). Identifier: NCT01970371. https://clinicaltrials.gov/ct2/show/NCT01970371?term=Plazomicin&rank=1 [accessed 19.01.16].
71. A.M. Nilius, L.L. Shen, D. Hensey-Rudloff, L.S. Almer, J.M. Beyer, D.J. Balli, and et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone Antimicrob Agents Chemother 47 2003 3260 3269
72. S.J. Harnett, A.P. Fraise, J.M. Andrews, G. Jevons, N.P. Brenwald, and R. Wise Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492 J Antimicrob Chemother 53 2004 783 792
73. ClinicalTrials.gov. Delafloxacin versus vancomycin and aztreonam for the treatment of acute bacterial skin and skin structure infections. Identifier: NCT01984684. https://clinicaltrials.gov/ct2/show/NCT01984684 [accessed 19.01.16].
74. G.H. Genzel, W. Stubbings, C.S. Stîngu, H. Labischinski, and R. Schaumann Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria Int J Antimicrob Agents 44 2014 420 423
75. ClinicalTrials.gov. Finafloxacin 300 mg twice a day (b.i.d.) versus ciprofloxacin 250 mg twice a day (b.i.d) in patients with lower uncomplicated UTI (uUTI) (FLUT). Identifier: NCT00722735. https://clinicaltrials.gov/ct2/show/NCT00722735 [accessed 19.01.16].
76. L.D. Saravolatz, G.E. Stein, and L.B. Johnson Telavancin: a novel lipoglycopeptide Clin Infect Dis 49 2009 1908 1914
77. M. Billeter, M.J. Zervos, A.U. Chen, J.R. Dalovisio, and C. Kurukularatne Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic Clin Infect Dis 46 2008 577 583
78. M.T. Guskey, and B.T. Tsuji A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin Pharmacotherapy 30 2010 80 94
79. G.G. Zhanel, D. Calic, F. Schweizer, S. Zelenitsky, H. Adam, P.R. Lagacé-Wiens, and et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin Drugs 70 2010 859 886
80. F.F. Arhin, I. Sarmiento, T.R. Parr Jr., and G. Moeck Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin J Antimicrob Chemother 64 2009 868 870
81. R.E. Mendes, L.N. Woosley, D.J. Farrell, H.S. Sader, and R.N. Jones Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010 Antimicrob Agents Chemother 56 2012 1639 1642
82. P. Prokocimer, P. Bien, K.A. Muñoz, and R. Aster Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Infectious Diseases Society of America (IDSA) Annual Meeting 25-28 October 2008, Washington, DC 2008 ASM Press Washington, DC
83. D. Steven, and R.T. Burdette Tedizolid: the first once-daily oxazolidinone class antibiotic Clin Infect Dis 61 2015 1315 1321
84. P. Prokocimer, C. De Anda, E. Fang, P. Mehra, and A. Das Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial JAMA 309 2013 559 569
85. G.J. Moran, E. Fang, G.R. Corey, A.F. Das, C. De Anda, and P. Prokocimer Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin structure infections (ESTABLISH-2): a randomized, double-blind, phase 3, non-inferiority trial Lancet Infect Dis 14 2014 696 705
86. ClinicalTrials.gov. TR-701 FA vs linezolid for the treatment of nosocomial pneumonia. Identifier: NCT0201940. https://clinicaltrials.gov/ct2/show/NCT02019420?term=TR701&rank=3 [accessed 19.01.16].
87. ClinicalTrials.gov. Safety and efficacy study of oxazolidinone to treat pneumonia. Identifier: NCT00640926. https://clinicaltrials.gov/ct2/show/NCT00640926?term=oxazolidinone&rank=1 [accessed 19.01.16].
88. ClinicalTrials.gov. Safety and efficacy study of oxazolidinones to treat uncomplicated skin infections. Identifier: NCT00646958. https://clinicaltrials.gov/ct2/show/NCT00646958?term=oxazolidinone&rank=2 [accessed 19.01.16].
89. World Health Organization WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health 2014 WHO Geneva, Switzerland http://www.who.int/mediacentre/news/releases/2014/amr-report/en/ [accessed 20.01.16]
90. M.E. Falagas, K.Z. Vardakas, K.P. Tsiveriotis, N.A. Triarides, and G.S. Tansarli Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections Int J Antimicrob Agents 44 2014 1 7
91. Y.H. Ku, M.F. Lee, Y.C. Chuang, C.C. Chen, and W.L. Yu In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum β-lactamases J Microbiol Immunol Infect 48 2015 699 702
92. M. Tumbarello, P. Viale, C. Viscoli, E.M. Trecarichi, F. Tumietto, A. Marchese, and et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy Clin Infect Dis 55 2012 943 950
93. H.S. Leu, J.J. Ye, M.H. Lee, L.H. Su, P.Y. Huang, T.L. Wu, and et al. Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii J Microbiol Immunol Infect 47 2014 406 411
94. R.G. Sawyer, J.A. Claridge, A.B. Nathens, O.D. Rotstein, T.M. Duane, H.L. Evans, and et al. Trial of short-course antimicrobial therapy for intraabdominal infection N Engl J Med 372 2015 1996 2005